EVQLV
EVQLV is a biotechnology company leveraging machine learning, computational biology, and software engineering to accelerate and reduce the cost of therapeutic antibody discovery. Their proprietary computational platform enables the generation of diverse, fully-human antibodies, facilitating faster, scalable, and cost-effective antibody design and development. EVQLV offers flexible partnerships for de novo antibody discovery, antibody engineering, and optimization, including humanization, affinity optimization, and epitope prediction. The company aims to transform antibody development by performing computational failure analysis to reduce costly lab failures and accelerate healing. EVQLV's technology supports a range of antibody formats and integrates easily with partners' pipelines, positioning it as an innovative leader in AI-driven antibody discovery and engineering.
EVQLV
EVQLV is a biotechnology company leveraging machine learning, computational biology, and software engineering to accelerate and reduce the cost of therapeutic antibody discovery. Their proprietary computational platform enables the generation of diverse, fully-human antibodies, facilitating faster, scalable, and cost-effective antibody design and development. EVQLV offers flexible partnerships for de novo antibody discovery, antibody engineering, and optimization, including humanization, affinity optimization, and epitope prediction. The company aims to transform antibody development by performing computational failure analysis to reduce costly lab failures and accelerate healing. EVQLV's technology supports a range of antibody formats and integrates easily with partners' pipelines, positioning it as an innovative leader in AI-driven antibody discovery and engineering.